Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IOVA Iovance Biotherapeutics, Inc.

盘前交易 09-30 06:42:51 EDT

14.45

+3.46

+31.48%

盘前14.54

+0.09+0.61%

06:42 EDT

最高15.30	最低12.78	成交量7,817万
今开12.79	昨收10.99	日振幅22.93%
总市值65.45亿	流通市值56.93亿	总股本4.53亿
成交额11.12亿	换手率19.84%	流通股本3.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IOVA","market":"US","secType":"STK","nameCN":"Iovance Biotherapeutics, Inc.","latestPrice":14.45,"timestamp":1790712000000,"preClose":10.99,"halted":0,"volume":78165836,"hourTrading":{"tag":"盘前","latestPrice":14.5379,"preClose":14.45,"latestTime":"06:42 EDT","volume":46569,"amount":672211.733043,"timestamp":1790764923996,"change":0.0879,"changeRate":0.006083,"amplitude":0.036678},"delay":0,"changeRate":0.3148316651501364,"floatShares":394000000,"shares":452971432,"eps":-0.705789,"marketStatus":"盘前交易","change":3.46,"latestTime":"09-30 06:42:51 EDT","open":12.79,"high":15.3,"low":12.78,"amount":1112447345.212532,"amplitude":0.229299,"askPrice":14.57,"askSize":50,"bidPrice":14.45,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.705789,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790775000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":14.45,"preHourTrading":{"tag":"盘前","latestPrice":14.5379,"preClose":14.45,"latestTime":"06:42 EDT","volume":46569,"amount":672211.733043,"timestamp":1790764923996,"change":0.0879,"changeRate":0.006083,"amplitude":0.036678},"postHourTrading":{"tag":"盘后","latestPrice":14.4214,"preClose":14.45,"latestTime":"19:59 EDT","volume":2438853,"amount":35239701.0466,"timestamp":1790726397156,"change":-0.0286,"changeRate":-0.001979,"amplitude":0.015225},"volumeRatio":5.683173472756888,"optionData":{"bulkOrders":[{"symbol":"IOVA","call":true,"expireDate":1797570000000,"strike":"15.0","timestamp":1790705095599,"price":2.65,"volume":10000,"amount":2650000,"type":"-"},{"symbol":"IOVA","call":false,"expireDate":1799989200000,"strike":"12.0","timestamp":1790693508062,"price":1.95,"volume":2000,"amount":390000,"type":"+"}]},"impliedVol":1.1253,"impliedVolPercentile":0.704},"requestUrl":"/m/hq/s/IOVA","defaultTab":"news","newsList":[{"id":"1121733946","title":"异动解读｜Iovance Biotherapeutics盘中上涨18.29%，上调全年营收指引超市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1121733946","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121733946?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:31","pubTimestamp":1790688687,"startTime":"0","endTime":"0","summary":"9月29日，Iovance Biotherapeutics盘中上涨18.29%，报12.96美元/股，成交额5088.31万美元。消息面上，公司最新上调全年营收指引，预计全年营收区间为4.1亿至4.2亿美元，较此前3.5亿至3.7亿美元的指引大幅提升，同时高于FactSet市场一致预期的4.028亿美元。Iovance Biotherapeutics是一家生物技术公司，专注于利用自体肿瘤浸润淋巴细胞开发和商业化针对转移性黑色素瘤等实体瘤的细胞治疗方法。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Iovance上调全年营收指引，股价强势上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153460492","title":"异动解读｜Iovance Biotherapeutics盘前上涨8.46%，上调全年营收指引超市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1153460492","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153460492?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:58","pubTimestamp":1790683127,"startTime":"0","endTime":"0","summary":"9月29日，Iovance Biotherapeutics盘前上涨8.46%，报11.94美元/股，成交额275.78万美元。消息面上，公司最新发布全年营收指引，预计全年营收区间为4.1亿至4.2亿美元，高于FactSet市场一致预期的4.028亿美元。此前公司二季度业绩已大幅超预期，营收约9930万美元创历史新高，每股亏损0.11美元优于市场预期的亏损0.13至0.14美元。Iovance Biotherapeutics是一家生物技术公司，专注于利用自体肿瘤浸润淋巴细胞开发和商业化针对转移性黑色素瘤等实体瘤的细胞治疗方法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"上调全年营收指引，Iovance盘前上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130392840","title":"异动解读｜Iovance Biotherapeutics盘中上涨8.05%，Q2业绩超预期及投行上调目标价持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1130392840","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130392840?lang=zh_cn&edition=full","pubTime":"2026-09-17 22:31","pubTimestamp":1789655479,"startTime":"0","endTime":"0","summary":"9月17日，Iovance Biotherapeutics盘中上涨8.05%，报10.665美元/股，成交额5973.48万美元，延续近期强势表现。消息面上，公司此前公布的第二季度财报大幅超预期，营收约9931万美元，远超市场预估的8783万美元，每股亏损0.11美元亦优于预期的0.14美元，创下历史最高季度营收纪录。核心产品Amtagvi单季收入约9100万美元，超过UBS预估的8000万美元。UBS随后将公司目标价由4美元上调至7美元，并预计管理层将在三季度业绩发布前上调全年收入指引至3.5亿至3.7亿美元以上。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Iovance业绩超预期，股价大涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106126664","title":"异动解读｜Iovance Biotherapeutics盘中上涨8.02%，Q2业绩超预期叠加投行上调目标价提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1106126664","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106126664?lang=zh_cn&edition=full","pubTime":"2026-09-15 00:55","pubTimestamp":1789404920,"startTime":"0","endTime":"0","summary":"9月15日，Iovance Biotherapeutics盘中上涨8.02%，报9.2899美元/股，成交额5794.68万美元。消息面上，公司此前公布的第二季度财报大幅超预期，营收约9931万美元，远超市场预估的8783万美元，每股亏损0.11美元亦优于预期的0.14美元，创下历史最高季度营收纪录。其核心产品Amtagvi单季收入约9100万美元，超过UBS预估的8000万美元。此后UBS将公司目标价由4美元上调至7美元，并预计管理层将在三季度业绩发布前上调全年收入指引至3.5亿至3.7亿美元以上。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Iovance业绩超预期，股价盘中大涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164706243","title":"异动解读｜Iovance Biotherapeutics盘中下跌8.06%，瑞银报告指Amtagvi面临竞争阻力引发回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1164706243","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164706243?lang=zh_cn&edition=full","pubTime":"2026-08-22 02:05","pubTimestamp":1787335528,"startTime":"0","endTime":"0","summary":"8月22日，Iovance Biotherapeutics盘中下跌8.06%，报8.2699美元/股，成交额1.75亿美元。消息面上，瑞银最新发布研究报告指出，公司核心产品Amtagvi面临新兴黑色素瘤疗法的竞争压力，且授权治疗中心的入驻周期仍长达六个月以上，增长前景蒙上阴影。尽管Q2 Amtagvi收入9100万美元超瑞银预估的8000万美元，瑞银仍维持中性评级，目标价由4美元上调至7美元，低于当前市场均值9.33美元。瑞银预计Q3 Amtagvi收入约9600万美元，全年总收入4.05亿美元，但强调市场竞争格局演变或持续施压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Iovance盘中下跌，瑞银警示竞争压力","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117491308","title":"异动解读｜Iovance Biotherapeutics盘中上涨9.07%，Q2业绩大超预期延续上行动能","url":"https://stock-news.laohu8.com/highlight/detail?id=1117491308","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117491308?lang=zh_cn&edition=full","pubTime":"2026-08-20 23:02","pubTimestamp":1787238172,"startTime":"0","endTime":"0","summary":"8月20日，Iovance Biotherapeutics盘中上涨9.07%，报8.715美元/股，成交额1.03亿美元。强劲的Q2财报表现持续驱动股价走强。消息面上，公司于8月6日发布第二季度财报，营收约9930万美元，大幅超出市场预期的8783万美元，创下历史新高；每股亏损0.11美元，优于分析师预期的亏损0.14美元。当前股价仍处于财报发布后的上行通道中。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Iovance业绩大超预期，股价强势上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107208733","title":"异动解读｜Iovance Biotherapeutics盘中上涨10.03%，Q2业绩大超预期延续上行动能","url":"https://stock-news.laohu8.com/highlight/detail?id=1107208733","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107208733?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:13","pubTimestamp":1787159599,"startTime":"0","endTime":"0","summary":"8月20日，Iovance Biotherapeutics盘中上涨10.03%，报7.735美元/股，成交额1.04亿美元。强劲的商业化表现推动股价在财报发布后持续走强，当前仍处于业绩驱动的上行通道中。Iovance Biotherapeutics是一家专注于自体肿瘤浸润淋巴细胞疗法开发与商业化的生物技术公司，主要用于治疗转移性黑色素瘤等实体瘤。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145971348","title":"Iovance Biotherapeutics 公布2026年第二季度创纪录营收约9900万美元，并披露业务进展及公司动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1145971348","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145971348?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:02","pubTimestamp":1786014141,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics（IOVA）近日发布了2026年第二季度的财务报告与业务更新。数据显示，该公司该季度营收飙升至约9900万美元，创下历史新高。与此同时，公司还披露了多项关键业务成就与战略调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105191515","title":"Iovance Biotherapeutics 提交补充招股书，拟增发普通股筹资上限约8970万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105191515","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105191515?lang=zh_cn&edition=full","pubTime":"2026-06-19 04:35","pubTimestamp":1781814938,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics公司已提交了一份销售协议补充招股说明书，计划增发普通股，最高筹资额约为8970万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126068070","title":"Iovance公司Amtagvi® (Lifileucel)获澳大利亚批准用于治疗晚期黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1126068070","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126068070?lang=zh_cn&edition=full","pubTime":"2026-06-04 04:05","pubTimestamp":1780517115,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics公司旗下产品Amtagvi® (Lifileucel)已获得澳大利亚监管机构的批准，用于治疗晚期黑色素瘤。这一进展标志着该细胞疗法在拓展全球市场准入方面迈出了关键一步，为当地晚期黑色素瘤患者提供了一种新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195027615","title":"Iovance Biotherapeutics 公布2026年第一季度积极业绩、业务成就及公司最新动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1195027615","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195027615?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:07","pubTimestamp":1778152054,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics 重点展示了其2026年第一季度的积极财务业绩、取得的重大业务成就以及重要的公司进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113419522","title":"财报前瞻｜Iovance Biotherapeutics, Inc.本季度营收预计小幅下滑，看多观点占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1113419522","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113419522?lang=zh_cn&edition=full","pubTime":"2026-04-30 14:38","pubTimestamp":1777531119,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics, Inc.将于2026年05月07日发布财报。市场一致预期本季度Iovance Biotherapeutics, Inc.营收为7,839.63万美元，同比下降4.05%；调整后每股收益为-0.15美元，同比改善37.43%；息税前利润为-6,667.17万美元，同比改善16.71%。公司上季度财报未给出对本季度的明确收入预测指引。公司当前主营业务亮点集中在“产品”业务，上季度收入为2.64亿美元。从近半年公开资料梳理的机构表述看，看多观点占优。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜Iovance Biotherapeutics, Inc.本季度营收预计小幅下滑，看多观点占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517189430","title":"Iovance Biotherapeutics, Inc.2024财年实现净利润-3.72亿美元，同比增加16.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517189430","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517189430?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363251,"startTime":"0","endTime":"0","summary":"3月8日，Iovance Biotherapeutics, Inc.公布财报，公告显示公司2024财年净利润为-3.72亿美元，同比增加16.22%；其中营业收入为1.64亿美元，同比增加13681.51%，每股基本收益为-1.28美元。从资产负债表来看，Iovance Biotherapeutics, Inc.总负债2.00亿美元，其中短期债务12.90百万美元，资产负债比为4.55，流动比率为3.75。机构评级：截至2025年3月8日，当前有13家机构对Iovance Biotherapeutics, Inc.目标价做出预测，其中目标均价为20.54美元，其中最低目标价为6.00美元，最高目标价为32.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000219a2647f65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000219a2647f65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517237539","title":"Iovance Biotherapeutics, Inc.盘中异动 下午盘股价大涨5.03%报4.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517237539","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517237539?lang=zh_cn&edition=full","pubTime":"2025-03-06 03:22","pubTimestamp":1741202536,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日03时22分，Iovance Biotherapeutics, Inc.股票出现波动，股价快速上涨5.03%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.06%。Iovance Biotherapeutics, Inc.公司简介：Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司，通过利用人体免疫系统识别和摧毁多种癌细胞的能力，为每位患者提供个性化治疗，开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306032216963b1b32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306032216963b1b32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IOVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677687","title":"Iovance Biotherapeutics, Inc.盘中异动 股价大跌5.07%报3.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677687","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516677687?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:39","pubTimestamp":1741099151,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时39分，Iovance Biotherapeutics, Inc.股票出现波动，股价急速跳水5.07%。Iovance Biotherapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.12%。Iovance Biotherapeutics, Inc.公司简介：Iovance Biotherapeutics Inc 是一家临床阶段的生物制药公司，通过利用人体免疫系统识别和摧毁多种癌细胞的能力，为每位患者提供个性化治疗，开创了治疗癌症的变革性方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223912989bae64&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223912989bae64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152554288","title":"异动解读 | Iovance Biotherapeutics股价盘中暴跌27.66%,分析师下调目标价引发担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1152554288","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152554288?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:43","pubTimestamp":1740753780,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics(IOVA.US)周五股价盘中大跌27.66%,引发广泛关注。\n\n导致股价暴跌的主要原因是,Baird分析师下调了IOVA的目标股价。Baird维持IOVA的优于大市评级不变,但将其目标价从24美元下调至20美元。\n\n分析师下调目标价反映出外界对该公司前景的担忧。作为一家细胞疗法生物科技公司,Iovance Biotherapeutics致力于开发创新的癌症免疫疗法产品。分析师对公司后续药品管线以及销售增长潜力的预期可能较暗淡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186787959","title":"异动解读 | Iovance Biotherapeutics (IOVA)盘前暴跌26.24%,安银下调目标价或为主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1186787959","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186787959?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:34","pubTimestamp":1740753296,"startTime":"0","endTime":"0","summary":"生物科技公司Iovance Biotherapeutics (IOVA.US)今日盘前股价大跌26.24%,引发市场关注。\n\n消息面上,资深投行Baird周四晚间下调了IOVA的目标价,由24美元下调至20美元,或许是导致这一盘前暴跌的主要原因。\n\n尽管Baird仍然维持IOVA \"优于大市\"的投资评级不变,但下调目标价反映了分析师对该公司未来业绩预期的担忧。IOVA目前正在开发针对多种癌症的临床晚期新型免疫疗法,处于重要阶段,后续的数据和监管审批结果将决定公司前景。而目标价下调无疑在一定程度上打击了投资者的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Iovance Biotherapeutics (IOVA)盘前暴跌26.24%,安银下调目标价或为主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514278327","title":"Baird：维持Iovance Biotherapeutics(IOVA.US)评级，由优于大市调整至优于大市评级, 目标价由24.00美元调整至20.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514278327","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514278327?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:28","pubTimestamp":1740752883,"startTime":"0","endTime":"0","summary":"Baird：维持Iovance Biotherapeutics(IOVA.US)评级，由优于大市调整至优于大市评级, 目标价由24.00美元调整至20.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28222848467015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514535563","title":"Iovance Biotherapeutics(IOVA.US)：2024年Q4财报实现营收7369.4万美元，前值为48.2万美元，预期值为7217万美元；每股收益为-0.26美元，前值为-0.45美元，预期值为-0.27美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514535563","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514535563?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:21","pubTimestamp":1740691300,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics(IOVA.US)：2024年Q4财报实现营收7369.4万美元，前值为48.2万美元，预期值为7217万美元；每股收益为-0.26美元，前值为-0.45美元，预期值为-0.27美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28052148442324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127368942","title":"Iovance Biotherapeutics 2024年第四季度GAAP每股亏损$(0.26)好于预期$(0.27)，销售额$7370万好于预期$7239.3万","url":"https://stock-news.laohu8.com/highlight/detail?id=1127368942","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127368942?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:10","pubTimestamp":1740690649,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics  报告称，季度每股亏损$，好于分析师一致预期的$，增幅为3.7%。这比去年同期的$每股亏损增加了42.22%。这比去年同期的$482.000千销售额增加了15.19千百分比。以上内容来自Benzinga Earnings专栏，原文如下：Iovance Biotherapeutics  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 3.7 percent. This is a 42.22 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $73.700 million which beat the analyst consensus estimate of $72.393 million by 1.81 percent.  T","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Iovance Biotherapeutics 2024年第四季度GAAP每股亏损$(0.26)好于预期$(0.27)，销售额$7370万好于预期$7239.3万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.iovance.com","stockEarnings":[{"period":"1week","weight":0.3581},{"period":"1month","weight":0.804},{"period":"3month","weight":2.6398},{"period":"6month","weight":3.2128},{"period":"1year","weight":5.4798},{"period":"ytd","weight":4.293}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0067},{"period":"3month","weight":0.0247},{"period":"6month","weight":0.1652},{"period":"1year","weight":0.1515},{"period":"ytd","weight":0.1207}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Iovance Biotherapeutics, Inc.是一家新兴的生物技术公司，专注于培养细胞，使用自体肿瘤浸润淋巴细胞（TIL）治疗转移性黑色素瘤等实体瘤的细胞治疗方法的发展和商业化。该公司于2007年9月17日在内华达州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.029113},{"month":2,"riseRate":0.545455,"avgChangeRate":0.158395},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.048412},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.016024},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.065253},{"month":6,"riseRate":0.5,"avgChangeRate":0.132853},{"month":7,"riseRate":0.666667,"avgChangeRate":0.041289},{"month":8,"riseRate":0.416667,"avgChangeRate":0.083754},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.008335},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.022017},{"month":11,"riseRate":0.727273,"avgChangeRate":0.07065},{"month":12,"riseRate":0.636364,"avgChangeRate":0.051779}],"exchange":"NASDAQ","name":"Iovance Biotherapeutics, Inc.","nameEN":"Iovance Biotherapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Iovance Biotherapeutics, Inc.(IOVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Iovance Biotherapeutics, Inc.,IOVA,Iovance Biotherapeutics, Inc.股票,Iovance Biotherapeutics, Inc.股票老虎,Iovance Biotherapeutics, Inc.股票老虎国际,Iovance Biotherapeutics, Inc.行情,Iovance Biotherapeutics, Inc.股票行情,Iovance Biotherapeutics, Inc.股价,Iovance Biotherapeutics, Inc.股市,Iovance Biotherapeutics, Inc.股票价格,Iovance Biotherapeutics, Inc.股票交易,Iovance Biotherapeutics, Inc.股票购买,Iovance Biotherapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Iovance Biotherapeutics, Inc.(IOVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Iovance Biotherapeutics, Inc.(IOVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}